Who Paid My Doc
Eva Reyes
Clinical Nurse Specialist, Women's Health Yucca Valley, CA Nurse Practitioner
NPI 1376767376 CMS profile 10653890
7180 Mohawk Trl, Yucca Valley, CA 92284
General payments
$77
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Eva Reyes of Yucca Valley, CA is reported in the CMS Open Payments database as having received $77 across 3 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $51 | 2 | |
| 2021 | General | $25 | 1 |
Beside peers
- Eva Reyes
- Clinical Nurse Specialist, Women's Health median
- Middle half of Clinical Nurse Specialist, Women's Health
- National median
In program year 2025, general payments to Eva Reyes were reported at $51. Among 41 Clinical Nurse Specialist, Women's Health profiles paid that year, the median was $151 and the middle half received between $37 and $248.
Show as a table
| Year | Eva Reyes | Clinical Nurse Specialist, Women's Health median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | — | — | $163 |
| 2020 | $0 | — | — | $114 |
| 2021 | $25 | $118 | $31–$278 | $132 |
| 2022 | $0 | $190 | $37–$353 | $149 |
| 2023 | $0 | $160 | $67–$321 | $160 |
| 2024 | $0 | $95 | $38–$226 | $164 |
| 2025 | $51 | $151 | $37–$248 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 1 drugPart D claims
17
Drug cost
$71
Branded share of claims
0%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Escitalopram Oxalate | Generic | 17 | $71 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,644 Part D prescribers listed as Certified Clinical Nurse Specialist; they describe a distribution and say nothing about conduct.
Records
3 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Clinical Nurse Specialist, Women's Health in California
Jose Chavez
Clinical Nurse Specialist, Women's Health · San Bernardino, CA
Ann Marie Navarra
Clinical Nurse Specialist, Women's Health · San Diego, CA
Olga Hidchenko
Clinical Nurse Specialist, Women's Health · San Francisco, CA
Sally Pitzer
Clinical Nurse Specialist, Women's Health · Ventura, CA
Claudia Ye
Clinical Nurse Specialist, Women's Health · Vista, CA
Cheryl Lee
Clinical Nurse Specialist, Women's Health · Orange, CA
Related records
Clinical Nurse Specialist, Women's Health in California
Practitioners in the same specialty and state, ranked by reported value.
All Clinical Nurse Specialist, Women's Health
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.